MAPT and Alzheimer disease: Riluzole decreased tau levels in a mouse model of AD with tauopathy [64], attenuated hippocampal acetylcholinesterase (AChE) activity and decreased the levels of several oxidative stress markers in rats after an intrahippocampal injection of Aβ [66].